empagliflozin
Showing 1 - 25 of 130
Glycogen Storage Disease Type IB Trial in Shanghai (Empagliflozin)
Recruiting
- Glycogen Storage Disease Type IB
- Empagliflozin
-
Shanghai, Shanghai, ChinaXinhua Hospital, Shanghai Jiao Tong University School of Medicin
Jul 17, 2023
Type 1 Diabetes Trial (Empagliflozin, Placebo)
Not yet recruiting
- Type 1 Diabetes
- Empagliflozin
- Placebo
- (no location specified)
Aug 31, 2023
Comparative Effectiveness of Empagliflozin in the US
Active, not recruiting
- Diabetes Mellitus, Type 2
- Empagliflozin
- +2 more
-
Boston, MassachusettsBringham Women Hospital
Jan 9, 2023
Kidney Transplant, Type 2 Diabetes Trial in United States (Empagliflozin)
Not yet recruiting
- Kidney Transplant
- Type 2 Diabetes
- Empagliflozin
-
Iowa City, Iowa
- +3 more
Aug 22, 2023
Emp-Activity: Empagliflozin Functional Capacity
Not yet recruiting
- Heart Failure
- Empagliflozin
- (no location specified)
Aug 5, 2022
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Trial (Empagliflozin,
Not yet recruiting
- Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
- Empagliflozin
- olanzapine
- (no location specified)
Jan 22, 2023
Ulcerative Colitis Trial (Empagliflozin, conventional treatment)
Not yet recruiting
- Ulcerative Colitis
- Empagliflozin
- conventional treatment
- (no location specified)
Nov 9, 2022
End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis Trial (Empagliflozin, Placebo)
Not yet recruiting
- End-stage Kidney Disease
- +7 more
- Empagliflozin
- Placebo
- (no location specified)
Jan 9, 2023
Metabolic-associated Fatty Liver Disease, Type 2 Diabetes Trial (Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide)
Not yet recruiting
- Metabolic-associated Fatty Liver Disease
- Type 2 Diabetes
- Empagliflozin
- +2 more
- (no location specified)
Oct 1, 2022
Cystic Fibrosis-related Diabetes, Cystic Fibrosis Trial in Minneapolis (Empagliflozin, Placebo Control)
Not yet recruiting
- Cystic Fibrosis-related Diabetes
- Cystic Fibrosis
- Empagliflozin
- Placebo Control
-
Minneapolis, MinnesotaUniversity of Minnesota
Nov 20, 2023
Novel Antidiabetic Medications and Their Effect on Liver
Completed
- Non-Alcoholic Fatty Liver Disease
- Liver Steatosis
- Empagliflozin
- +2 more
-
Athens, Attiki, Greece"Hippocration" General Hospital of Athens
Jul 13, 2023
PreDiabetes, Prediabetic State, Overweight and Obesity Trial in Corvallis (Empagliflozin, Multivitamin-Placebo)
Recruiting
- PreDiabetes
- +2 more
- Empagliflozin
- Multivitamin-Placebo
-
Corvallis, OregonOregon State University
Jul 19, 2022
MDD Trial in New York (Empagliflozin)
Not yet recruiting
- Major Depressive Disorder
- Empagliflozin
-
New York, New YorkNYU Langone Health
Feb 24, 2023
Polycystic Kidney, Autosomal Dominant Trial in Aurora (Empagliflozin, Placebo)
Not yet recruiting
- Polycystic Kidney, Autosomal Dominant
- Empagliflozin
- Placebo
-
Aurora, ColoradoUniversity of Coloardo Anschutz Medical Campus
Aug 18, 2022
Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD) Trial run by the National Institute of Allergy and
Recruiting
- Crohn's Disease
- +2 more
- Empagliflozin
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Empagliflozin in Type 2 Diabetes Population With and Without
Not yet recruiting
- Diabetes Mellitus, Type 2
- Empagliflozin
- +3 more
-
Durham, North CarolinaDuke Clinical Research Institute
Aug 8, 2022
Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
-
Ingelheim am Rhein, GermanyBoehringer Ingelheim International GmbH
Aug 19, 2022
Renal Insufficiency, Chronic Trial in Mansoura, Tanta (Metformin, Empagliflozin, Standard therapy)
Recruiting
- Renal Insufficiency, Chronic
- Metformin
- +2 more
-
Mansoura, Dakahlia Governorate, Egypt
- +1 more
May 12, 2022
Postprandial Hypoglycemia Trial in Basel (empagliflozin, anakinra, saline subcutaneous (s.c.) ())
Recruiting
- Postprandial Hypoglycemia
- empagliflozin
- +3 more
-
Basel, SwitzerlandDepartment of Endocrinology, Diabetes and Metabolism, University
Apr 19, 2022
Type 2 Diabetes to Assess Risk of Liver Injury, Kidney Injury,
Completed
- Diabetes Mellitus, Type 2
- Empagliflozin
- DPP-4 inhibitors
-
One Or Multiple Sites, United KingdomRTI health solutions
Aug 2, 2022
Healthcare Cost and Resource Utilization in Type 2 Diabetes and
Withdrawn
- Diabetes Mellitus, Type 2
- Cardiovascular Diseases
- empagliflozin
- +2 more
-
Ridgefield, ConnecticutBoehringer Ingelheim Pharmaceuticals Inc
May 30, 2022
Empa PASS on Urinary Tract Malignancies
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- +2 more
-
Helsinki, Finland
- +2 more
Aug 8, 2022